Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 9/20 | 0.54 |
| ▸ | BTK | Q06187 | 8/20 | 0.54 |
| ▸ | LYN | P07948 | 6/20 | 0.43 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23884991 | 0.90 | BTK (0.43) | SRCBTKLYNSCDFGFR1 | |
| SCHEMBL23885005 | 0.80 | SRC (0.54) | SRCBTKLYNFGFR1 | |
| SCHEMBL23884990 | 0.79 | BTK (0.43) | SRCBTKLYNSCDPIK3CA | |
| SCHEMBL4425301 | 0.79 | SRC (0.56) | SRCBTKLYN | |
| SCHEMBL14999843 | 0.78 | BTK (0.51) | SRCBTKLYN | |
| SCHEMBL14999862 | 0.76 | BTK (0.49) | SRCBTKLYN | |
| SCHEMBL29800861 | 0.76 | METAP2 (0.42) | SRCBTKLYNSCDFGFR1 | |
| SCHEMBL28389300 | 0.76 | METAP2 (0.42) | SRCBTKLYNSCDFGFR1 | |
| SCHEMBL14999721 | 0.76 | BTK (0.49) | SRCBTKLYNSCDFGFR1 | |
| SCHEMBL15000236 | 0.76 | KIT (0.49) | SRCBTKLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315869-A1 | COMPOUNDS AND METHODS FOR CSK MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2021-10-14 | — | — | US | disclosed |
| WO-2021202900-A1 | 1,6-NAPHTHYRIDINE COMPOUNDS AND METHODS FOR CSK MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315869-A1 | COMPOUNDS AND METHODS FOR CSK MODULATION AND INDICATIONS THEREFOR | MC2R, SLC10A1, SLC10A2 | SRC 1523/4885BTK 974/4885LYN 3545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.